MOUNTAIN VIEW, Calif., April 21, 2015 /PRNewswire/ -- The increase of diabetes due to sedentary lifestyles and healthcare reforms the market for self-monitoring blood glucose (SMBG) meters and strips is expanding. However, several challenges limit the revenue potential for this market. Availability of inexpensive generic test strips has intensified competition and strained participants' profit margins.
New analysis from Frost & Sullivan, US Self-monitoring Blood Glucose Market (http://bit.ly/1AvfQ4W), finds the market earned revenue of $4.04 billion in 2014 and estimates this to reach $4.18 billion in 2016. The study covers meters and strips. Over 90% of the revenues are contributed by the strips market.
For complimentary access to more information on this research, please visit: http://bit.ly/1HAYb2M.
"Generic test strip market coupled with slash in Medicare reimbursement and national mail order program will affect the market until 2016," said Frost & Sullivan Life Sciences Senior Industry Analyst Divyaa Ravishankar. "Other threats to the market include innovations in continuous monitoring and noninvasive methods of testing being pursued by IT companies like Google."
Together, the reimbursement cut and CBP will have many consequences, including the exit of independent retail pharmacy communities from the program. Medicare's national mail-order program inhibits retail pharmacies from delivering test supplies to frail and homebound patients on the same day. Additionally Medicare patients will not have access to diabetes supplies from independent pharmacies. The overall result is a reduced accessibility for patients and a drop in the sales of SMBG products.
Given the reimbursement reductions and sequestration cuts in the US, non-invasive methods might replace the SMBG market in the long-run. As alternative markers at the point of care – such as glycated albumin tests – can ease reimbursement issues associated with the market and provide meaningful care in type 2 diabetic patients, these products could also eat into SMBG's market share.
Spot monitoring provides a snapshot of blood glucose activity, research has shown that trend data is more useful in determining the long-term treatment regimen for diabetes. Several large companies are investing in continuous monitoring technologies that are proving more useful in determining long-term treatment regimens for diabetes.
"Finger-stick tests currently complement continuous devices and these invasive meters losing share to continuous devices is a long term possibility," noted Ravishankar. "Non-invasive methods are becoming popular and may replace the SMBG market in the long run, given the reimbursement reductions and sequestration cuts in the United States. Alternative markers at the point of care for instance the glycated albumin tests can ease the reimbursement issues associated with the market and also provide a meaningful care in Type 2 diabetic patients."
US Self-monitoring Blood Glucose Market is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. Frost & Sullivan's related studies include: US Liquid Handling Market, US Hemostasis Market, and Global Analysis of Ebola Disease. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
US Self-monitoring Blood Glucose Market
Corporate Communications – North America
E: [email protected]
SOURCE Frost & Sullivan